A passion for


We are constantly innovating our people, project management and technology models leading to outstanding results for our collaborators. The world’s first app based technology platform Chemistry in the CloudTM enables us to work together to make faster decisions. Our deep understanding that an early and intensive evaluation of target molecules based on real insight into the science will lead to faster downstream execution. The result is a higher throughput of successful drug-like compounds.

Organic chemistry


o2h is a highly reputed service provider of mg/g scale discovery chemistry. We have partnered with a range of well known pharmaceutical and biotechnology companies from Europe, USA and Japan.

The specialised team at o2h has a broad array of experience in preparing small molecule NCEs with the requisite high quality specifications. It is proficient in utilising perse methodologies, including the synthesis of singles, multi-step, small arrays as well as focused libraries. Our scientific team is also experienced in parallel construction of focused libraries for use in hit-to-lead and lead optimisation projects.

The delivery of all our compounds is accompanied with complete characterisation data including, but not limited to, high-field NMR, mass and purity by LC-MS/HPLC/GC.

Access to databases such as SciFinder and Beilstein provides the team with all the necessary current information to modify and develop new synthetic routes.

o2h has experience of a wide range of chemistry including:

  • Chiral chemistry
  • Aliphatic, aromatic and heterocyclic chemistry
  • Carbohydrate chemistry
  • Peptide chemistry
  • Steroid chemistry
  • Nucleoside chemistry
  • Combinatorial chemistry
  • Natural product chemistry
  • Fragment libraries
  • Metabolite/impurity/reference synthesis
  • Microwave chemistry

Medicinal chemistry

Medicinal chemistry expertise available at o2h includes hit identification, hit-to-lead optimisation, lead generation, and lead optimisation. All of these can be accessed as stand-alones or as a part of an integrated drug discovery project.

Hit identification/lead generation projects have involved ligand design for customer-defined targets, synthesis of homologous or diverse series of compounds, design and generation of structurally related compounds, combinatorial synthesis of general as well as focused libraries and search for surrogates of core chemical scaffolds.

Hit-to-lead projects typically involve confirmation of a genuine structure-activity relationship (SAR) and reducing structural/pharmacological liabilities. o2h has the capability to synthesise small focused arrays of compounds in sufficient quantities to allow clients to rapidly screen these compounds for ADME and in vitro biological activity (primary as well as secondary screenings).

For projects advancing to lead optimisation phase, chemists at o2h work intensively with their biology counterparts to produce compounds which closely match the desired target product profile. Typically, this involves a thorough search of prior art and assuring patentability, generation of back-up series and leading the compounds to in vivo proof-of-concept. Our biologists can assist in generating in vivo experimental models recapitulating a particular human pathological condition, designing and efficiently executing PK/PD, toxicology and other relevant pharmacological studies to advance these compounds further.

Computational chemistry


Computational chemists at o2h work at providing stand-alone services to our clients with in silico based screening projects as well as supporting medicinal chemistry projects. Computational chemistry expertise includes molecular modelling, virtual screening and drug designing.

Virtual screening services include target identification, in silico drug-likeness, screening of client/commercial databases to identify focused lead/hit compounds and docking studies to prioritise hits for in vitro studies.

Drug designing to support hit generation and lead optimisation are applied to augment medicinal chemistry design efforts and help guide structural modifications to enhance potency, selectivity and drug-like characteristics. Close cooperation between our molecular modellers and medicinal chemists plays a vital role in this process.

Apart from these, we also support designing target-focused libraries, target modelling, molecular dynamic simulations and developing highly predictive 3D-QSAR models based on target and therapeutic areas.

Chemical biology

o2h has recently expanded its capability to support several chemical biology projects to deliver bespoke, high quality tools to positively impact target validation and mechanistic understanding.

This includes cutting edge research to prepare key diverse intermediates alongside developing optimised construction methods to prepare these complex molecules in the most efficient manner. The involvement of our analytical group plays an essential role to ensure these tools are isolated in the most appropriate way to meet the required compound specifications and deliver high quality biological data.

Antibody drug conjugate


Bespoke Intermediates for ADCs 

Building on our expertise to support small molecules drug discovery programs, we have now extended our service offering to projects in ADC space as outlined below.

Our service offering includes the synthesis, development and scale-up of bespoke Linker, Linker-Reagent, Reagents, Peptide scaffolds, and associated intermediates to meet our collaborator's specifications for their R&D needs.

Discovery News

02 Nov 2017

The quest to positively benefit the lives of patients in the world of drug discovery means finding novel therapeutics for unmet medical needs. The biotech and pharma companies have been increasingly resorting to external innovation to supplement their pipeline of ideas and turbocharge their research-based businesses with enterprising partners with complementary ideas, capabilities and services. It is therefore hardly surprising that the top medicinal chemists working in both large and small companies have multiple partners across different continents and time-zones. To deliver these iterative discovery projects often entails detailed co-ordination of inter-related activities and extensive multi-tasking. Project management is the hub that allows these complex matrices of networks to communicate and for the project to successfully advance. In today’s fast paced and technologically advanced digital world, providing the project manager the right tools to make informed decisions is key to successful delivery. o2h Discovery’s innovative app Chemistry in the Cloud TM builds upon the latest advances in secure cloud-based mobile technology and integrates project management of external drug discovery programs. The app enables communication between the various scientific stakeholders essential to successful project advancement leading to faster decision making. It negates the onerous tasks of weeding out critical information that is required to take a complex decision by extracting the information from large data intensive reports and databases. These crucial decision points are now just a ‘tap/swipe-of-the-finger’ in the Chemistry in the CloudTM app so that they can speedily execute tasks anytime, anywhere. The communication covering a gamut of research activities in relation to process of research now truly happens in 24/7 real-time. o2h announced a worldwide launch and first live demonstration of our revolutionary project management app – Chemistry in the Cloud TM on 10th September 2017 at the 19th RSC/SCI Cambridge medicinal chemistry conference to some of world’s top scientists. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules. https://www.linkedin.com/in/sunil-shah-4bb225/detail/recent-activity/shares/ Nilesh Dagia (nilesh@o2h.com) is the COO @ o2h Discovery

02 Nov 2017

Fast decision making, anytime, anywhere… For More Information - Press Release - Chemistry in the cloud

04 Oct 2017

IOTA has been funded to establish a Glioblastoma “drug bank” as part of their membership of the WINDOW Consortium. More information about the WINDOW project can be found at: http://www.sanger.ac.uk/news/view/brain-tumour-charity-grants-window-consortium-15-million-new-research-combination or IOTA website:http://www.iotapharma.com/news-details.aspx?id=20


November 1st 2017 10:11:52

O2h Discovery: Chemistry in the Cloud™ - The World's First App To Project Manage Drug Discovery - https://t.co/LP0dpstmFI


November 13th 2017 12:11:27

Read our COO Nilesh Dagia's thoughts on our App Launch - "CHEMISTRY IN THE CLOUD TM – The World’s First APP to Pro… https://t.co/kQpz3s74Om

o2h culture, people & careers

Get o2h latest updates